Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / Cognitive peptides

122 In the index

Davunetide DAVU

An experimental protective compound tested in human trials for a brain disease called progressive supranuclear palsy and for memory problems. The main trial failed to show it worked, and development for those uses was dropped.

Also known as NAP, AL-108

Effects Focus
Routes Nasal
Legal status Unapproved / investigational
WADA Not listed

Molecular Structure of C36H60N10O12

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula
C36H60N10O12
Molar mass
824.9
CAS
211439-12-2
PubChem CID
9832404

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not approved; trial doses studied then discontinued
Reported range Phase II/III trials: intranasal doses up to 30 mg
Route Intranasal
Frequency Daily (trial protocol)
Duration Trial durations of up to a year

Failed its pivotal Phase II/III trial for progressive supranuclear palsy; development was discontinued. Not an approved product.

Where this comes from Published Phase II/III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.